Ignite Creation Date:
2024-05-06 @ 3:07 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04525326
Status:
UNKNOWN
Last Update Posted:
2020-08-25
First Post:
2020-08-21
Brief Title:
Conversion Therapy of RASBRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
A Prospective Study on the Conversion Therapy of Ras BRAF Wild Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases Standard Chemotherapy Plus Cetuximab VS Standard Chemotherapy Plus Bevacizumab
Status:
UNKNOWN
Status Verified Date:
2020-08
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The prognosis of patients with metastatic right-sided colon cancer is worse than that of patients with metastatic left-sided cancer Different guidelines have different recommendations on specific conversion therapy for colorectal liver metastases The United States NCCN guidelines do not recommend standard chemotherapy combined with anti EGFR monoclonal antibody for patients with right colon cancer The European ESMO guidelines recommend that patients with Ras BRAF wild-type right-sided colon cancer should first consider three drugs bevacizumab but considering the objective response rate results standard chemotherapy anti EGFR monoclonal antibody is still one of the choices China CSCO guidelines recommend standard chemotherapy bevacizumab and also recommend standard chemotherapy cetuximab for patients with right-sided colon cancer
Therefore the targeted therapy for RAS BRAF wild-type metastatic right colon cancer is still controversial Therefore we are ready to carry out the clinical trial of cetuximab and bevacizumab in conversion therapy for RAS BRAF wild-type metastatic right colon cancer The conversion resection rate is the primary point and the objective response rate perioperative safety and long-term survival are the secondary points
Therefore the targeted therapy for RAS BRAF wild-type metastatic right colon cancer is still controversial Therefore we are ready to carry out the clinical trial of cetuximab and bevacizumab in conversion therapy for RAS BRAF wild-type metastatic right colon cancer The conversion resection rate is the primary point and the objective response rate perioperative safety and long-term survival are the secondary points
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None